- Academic Editor
-
-
-
Announcements
Open Access
Opinion
Can Liquid Biopsy Cancer Research Offering Personalized Cancer Treatment in Gynecology be a Realistic Expectation?
Show Less
1
Women and Babies Clinic, Central Building, Hong Kong, China
2
Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China
3
Department of Obstetrics & Gynecology, Hong Kong University, Hong Kong, China
*Correspondence: fwong3@hotmail.com.hk (Felix Wong)
Clin. Exp. Obstet. Gynecol. 2023, 50(6), 132;
https://doi.org/10.31083/j.ceog5006132
Submitted: 10 February 2023 | Revised: 26 March 2023 | Accepted: 29 March 2023 | Published: 27 June 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
This paper encourages understanding a non-invasive technology—the “Liquid biopsy”, including circulating tumor cells (CTCs) and circulating tumor DNA (ct DNA) technology, that can help diagnose early cancers, cancer relapse, and resistance to chemotherapy. This paper reviews various CTCs and ct DNA studies in the literature about their applications in gynecological cancers. Hopefully, further translational cancer research in gynecology will enable personalized cancer treatment to become a realistic expectation.
Keywords
gynecological cancers
liquid biopsy
circulating tumor cells
circulating tumor DNA